The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has
been considered the standard of care for more than a decade. Second generation
compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients
as well as those who fail imatinib. Bosutinib and ponatinib have also become available as
second line options. With five agents from which to choose, selecting a TKI has become a …